Immune Response Linked to Key Enzyme
News Apr 12, 2013
The family of enzymes, called Sir2, has been extensively studied for their role in aging.
The research, published April 4 in the journal Nature, was led by senior author Hening Lin, associate professor of chemistry and chemical biology. Lin and colleagues reported that the enzyme Sirtuin-6 (SIRT6) promotes the secretion of a signaling molecule called tumor necrosis factor-alpha (TNF), which is important for triggering immune responses in mammalian cells.
Rheumatoid arthritis, for example, is associated with is an overabundance of TNF. The molecule also promotes cancer cell death. The study found that SIRT6 promotes TNF secretion by removing long-chain fatty acyl groups from protein lysine residues.
It was not previously known that SIRT6 could play this key chemical role in the TNF promotion process. Based on the findings, researchers may one day look to manipulate SIRT6 in therapies to treat diseases.
This is the first study to explain how such long-chain fatty acyl groups are removed in mammalian cells.
“This long-chain fatty acyl lysine modification was reported 30 years ago, but no one knew its physiological function, so our finding helps explain that,” Lin said.
The study was funded in part by the National Institutes of Health. Co-authors include researchers from the University of Hong Kong, Rockefeller University and Harvard Medical School. The study’s lead authors were Hong Jiang, research associate, Saba Khan, graduate student, both in Lin’s lab, and Yi Wang, a researcher at the University of Hong Kong.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.